CClinicalTrials.gg
CompletedNCT06214351Updated Apr 29, 2026

Mobile Midwifery Application Offered in the Prenatal Period

An interventional study of Use of mobile midwifery application in Mobile Application, sponsored by Agri Ibrahim Cecen University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Agri Ibrahim Cecen University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

In this study, the development of a mobile application for prenatal midwifery care and the examination of the effect of the developed mobile application on the stress, fear of childbirth, readiness for childbirth, and satisfaction with care of pregnant women are aimed. The research has a randomized controlled experimental design. Research data will be collected between December 2023 and October 2024 at the Obstetrics and Gynecology Clinic of Ağrı Training and Research Hospital. The universe of the research will consist of pregnant women who apply to the Obstetrics and Gynecology Clinic of the relevant hospital. The sample of the research consists of pregnant women who meet the inclusion criteria and volunteer to participate in the research. A priori power analysis was conducted to determine the sample size of the research. Cohen's standardized effect size reference method was selected in the power analysis. It was calculated that 102 pregnant women (Experimental group: 51, Control group: 51) should be included in order to achieve 80% power with a 95% confidence interval at a significance level of 0.05. In order to account for possible data losses, it was decided to collect data from a total of 128 individuals by including an additional 25% reserve sample in this number. During the follow-up period, 19 participants from the experimental group were withdrawn due to failure to use or deletion of the application (n=10), incomplete questionnaires (n=4), miscarriage (n=3), fetal death (n=1), and preterm labor (n=1). In the control group, 12 participants were withdrawn due to miscarriage (n=4) and incomplete completion of survey forms (n=8). Due to the exclusion and withdrawal criteria, the study was completed with 107 participants (Experimental: 50, Control: 57). The sample of the research will be selected by randomization among those who meet the specified research criteria. The assignment of participants to the experimental and control groups will be done through randomization. For randomization, the Random Integer Generator method in the Numbers subheading of the https://www.random.org site will be used to create single-group columns between 1 and 128 in the system. In the data collection stage of the study, an Introductory Information Form, Risk Assessment Form of the Ministry of Health of the Republic of Turkey, Visual Analog Patient Satisfaction Scale, Tilburg Pregnancy Distress Scale, Prenatal Self-Evaluation Scale - Fear of Childbirth and Sub-dimensions of Readiness for Childbirth, and Mobile Application Evaluation Form will be used.

Read the detailed description

Experimental Group: Pregnant women in the experimental group will have a mobile application installed on their smartphones.

Control Group: Pregnant women in the control group will receive routine antenatal care.

Pregnant women who meet the inclusion criteria of the study will be provided with information about the purpose, content, and application of the study. Pregnant women in the experimental and control groups will be included in the study. At this stage, both groups will fill out the Personal Information Form, the Birth Fear and Birth Readiness sub-scales of the Prenatal Self-Evaluation Scale, the Tilburg Pregnancy Distress Scale, and the Risk Assessment Form of the Ministry of Health of the Republic of Turkey.

At the end of the information process, informed consent will be obtained from pregnant women. Pregnant women will be assigned to experimental and control groups using a simple random table from the www.random.org website.

In the last trimester of pregnancy (weeks 38), the Birth Fear and Readiness sub-scales of the Prenatal Self-Assessment Scale, Visual Analog Patient Satisfaction Scale, and Tilburg Pregnancy Distress Scale will be administered to both the control and experimental groups. Pregnant women in the experimental group will also complete the mobile application evaluation form.

02

Conditions studied

  • Mobile Application

Keywords

  • Midwife
  • Prenatal period
  • Mobile application
  • Fear of birth
  • Midwifery care
  • Readiness
03

In context

Lead sponsor

Agri Ibrahim Cecen University is the lead sponsor of 39 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

Being literate Being 18 years or older Being primigravida Having a single fetus Being in the second trimester of pregnancy Having a smartphone and having the ability to use it effectively Having internet access Being open to communication Not having a diagnosed psychiatric disease Volunteering to participate in research

Exclusion criteria

Exclusion Criteria:

Being illiterate Being multiparous Having a High Risk Pregnancy according to the "Risk Assessment Form" of the Ministry of Health of the Republic of Turkey Having a diagnosed psychiatric disorder don't have a disease

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Experimental Group

    A mobile application will be installed on the smartphones of the pregnant women in the experimental group. The mobile application will be installed on the phones of the pregnant women in the experimental group. (The mobile application will be downloaded from the "Play Store" for Android users and from the "App Store" for iOS users). Information about the application will be provided and any questions from the pregnant women will be answered. Pregnant women will be free to access the application at any time during the study.

    Other: Use of mobile midwifery application

  • No intervention
    Control Group:

    Pregnant women in the control group will receive routine antenatal care. Routine antenatal care will be provided to pregnant women in the control group.

Interventions

  • OtherUse of mobile midwifery application

    Pregnant women in the experimental group will have a mobile midwifery application installed on their smartphones. The pregnant woman will be able to reach the research midwife 24/7. With the informative content and algorithm mechanism in the application, she will be able to provide individual care and detect early signs of danger, enabling her to seek medical attention.

06

What researchers measure

Primary outcomes

  1. Visual Analogue Patient Satisfaction Scale

    The patient satisfaction scale was designed to measure the patient's satisfaction with the given care practices. The scale has numbers from 1 to 10 on a vertical line. Number 1 symbolizes complete dissatisfaction and number 10 symbolizes high level of satisfaction.

    Time frame: It will be taken at 38 week of pregnancy.

  2. Tilburg Pregnancy Distress Scale

    It is used to determine distress (stress, anxiety, depression) during pregnancy. The scale consists of a total of 16 items. Each item of the scale is rated as a 4-point Likert type ranging from "very often" (0 points), "quite often" (1 point), "occasionally" (2 points), "rarely or never" (3 points). A total score of 28 or above from the scale enables the diagnosis of pregnant women who are at risk for distress (depression, anxiety, stress).

    Time frame: This form will be collected at the first meeting with the pregnant woman and at 38 week of pregnancy.

  3. Prenatal Self-Assessment Scale- Fear of Birth and Birth Readiness Sub-Dimensions

    The scale is used to evaluate the adaptation of pregnant women to pregnancy and motherhood. The "Fear of Birth" and "Readiness for Birth" subscales in the scale will be used. Items are evaluated with scores ranging from "1" to "4" (4: "Describes very much," 3: "Partly describes," 2: "Somewhat describes," 1: Does not describe at all"). The lowest score to be taken separately in the fear of birth and birth readiness sub-dimensions is 10 and the highest score is 40.

    Time frame: This form will be collected at the first meeting with the pregnant woman and at 38 week of pregnancy.

  4. Mobile Application Evaluation Form

    This is an evaluation form consisting of 8 questions by which pregnant women participating in the study can evaluate the application.

    Time frame: The questionnaire will be filled out for pregnant women in the experimental group at the end of the study (38 week of pregnancy).

  5. Risk Assessment Form of the Ministry of Health of the Republic of Turkey

    With this form, it will be determined whether the pregnant women who will participate in the study are at high risk. Pregnant women in the high risk group will not be included in the study.

    Time frame: It will be filled in at the first meeting with the pregnant woman.

07

Study locations

1 site
  • AgriIbrahimCecenU
    Ağrı, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06214351
Lead sponsor
Agri Ibrahim Cecen University
Collaborators
Ataturk University
Responsible party
Rumeysa ÖZAYABAKAN (Lecturer, Agri Ibrahim Cecen University) — Principal investigator
First posted
Jan 19, 2024
Start date
Dec 1, 2023
Primary completion
Oct 15, 2024
Completion
Oct 15, 2024
Last update
Apr 29, 2026

Study contacts

Ayla KANBUR
principal investigator · Ataturk University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion